Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-10-30
2010-02-16
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S257000, C544S225000
Reexamination Certificate
active
07662820
ABSTRACT:
Provided herein is dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon. Also provided herein is the compound dipterinyl calcium pentahydrate (DCP) or an analog or polymorph thereof.
REFERENCES:
patent: 6358953 (2002-03-01), Moheno
patent: 6844343 (2005-01-01), Pfleiderer et al.
Mitsumi, et al., Molecular Crystals & Liquid Crystals Science & Technology, Section A: Molecular Crystals & Liquid Crystals (1996), 276, 229-235.
Cameron, D.A. et al., “Tamoxifen induced apoptosisin ZR-75 breast cancer xenografts antedates tumour regression,” Breast Cancer Res. Treat. 45(20:99-107 (1997).
Emi, M. et al., “Targeted therapy against Bc1-2-related proteins in breast cancer cells,” Breast Cancer Res. 7(6):R940-R952 (2005).
Han, G.Z. et al., “Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer,” Cancer Res. 65(2):387-393 (2005).
Hoke, E.M. et al., “Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin,” Free Radic. Biol. Med. 39(3):403-411 (2005).
Jones, L.W., “Effects of exercise training on antitumor efficacy of doxorubicin in MDA-MB-231 breast cancer xenografts,” Clin. Cancer Res. 11(18):6695-6698 (2005).
Jordan, V.C. et al., “Immune-deficient animals to study “hormone-dependent” breast and endometrial cancer,” J. Steroid Biochem. 34(1-6):169-176 (1989).
Kokolis et al., “Pteridine and Riboflavin in Tumor Tissue and the Effect of Chloramphenicol and Isoxanthopterin,” Z. Naturforsch. B27:292-295 (1972).
LaMontagne, K.R. et al., “Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models,” Mol. Cancer Ther. 5(2):347-355 (2006).
Lewisohn et al., “The Action of Xanthopterin on Tumor Growth,” Proc. Soc. Exp. Biol. Med. 56:144-145 (1944).
Liao, Y. et al., “Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer,” Cancer Gene Ther. 11(9):594-602 (2004).
Mewani, R.R. et al., “Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models,” Int. J. Oncol. 24(5):1181-1188 (2004).
Milacic, V. et al., “A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts,” Cancer Res. 66(21):10478-10486 (2006).
Robinson, S.P. et al., “Preclinical studies with toremifene as an antitumor agent,” Breast Cancer Res. Treat. 16 (Suppl):S9-S17 (1990).
Robinson, S.P. et al., “Antiestrogenic action of toremifene on hormone-dependent,—independent, and heterogeneous breast tumor growth in the athymic mouse,” Cancer Res. 49(7):1758-1762 (1989).
Sweeney, C.J. et al., “The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer,” Mol. Cancer Ther. 4(6):1004-1012 (2005).
Taras, T.L., et al., “In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer,” J. Steroid Biochem. Mol. Biol. 77(4-5):271-279 (2001).
Warnberg, F. et al., “Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo,” Breast Cancer Res. 8(2):R21-R31 (2006), Epub Apr. 12, 2006.
Winkler et al., “Calcium-pterin suppresses mitogen-induced tryptophan degradation and neopterin production in peripheral blood mononuclear cells,” Immunobiology 211:779-784 (2006).
Woessner, R. et al., “Comparison of three approaches todoxorubicin therapy: free doxorubicin, liposomal doxorubicin, and beta-glucuronidase-activated prodrug (HMR 1826),” Anticancer Res. 20(4):2289-2296 (2000).
Yamamoto, D. et al., “Synergistic effects induced by cycloprodigiosin hydrochloride and epirubicin on human breast cancer cells,” Breast Cancer Res. Treat. 72(10):1-10 (2002).
Yen, W.C. et al., “The selective retinoid X receptor agonistbexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma,” Mol. Cancer Ther. 4(5):824-834 (2005).
Crispini, A. et al., “Hdrogen-bonding network in metal-pterin complexes: Synthesis and characterization of water-soluble octahedral nickel and cadmium pterine derivatives,” Crystal Growth & Design 5(4):1597-1601 (2005).
Mitsumi, M. et al., “Metal-pteridine complexes having three-dimensional hydrogen-bonded networks,” Inorg. Chem. 34(12):3367-3370 (1995).
PCT/US07/23012 Search Report dated Jun. 17, 2008.
Moheno, P., et al., “Plasma Cytokine Changes Induced by the Antitumor Agents Dipterinyl Calcium Pentahydrate (DCP) and Related Calcium Pterins,” Immunology, article in press, received Apr. 2, 2008.
Moheno, P., et al., “Plasma Cytokine Changes Induced by the Antitumor Agents Dipterinyl Calcium Pentahydrate (DCP) and Related Calcium Pterins,” Pteridines 19 (2):49 (2008).
Moheno, P., et al., “Cytokine and IDO Metabolite Changes Effected by Calcium Pterin During Inhibition of MDA-MB-231 Xenograph Tumors in Nude Mice,” International Journal of Pharmaceutics 355:238-248 (2008).
Moheno, P., et al., “Mechanism of Action Studies with the Antitumor Agent Calcium-Pterin,” Pteridines 18(2):50 (2007).
Moheno, P., et al., “Role of Calcium Pterin in Natural Killer (NK) Cell Activation and Indoleamine 2,3-Dioxygenase (IDO) Modulation for Antitumor Activity,” Pteridines 16:140 (2005).
Moheno, P., et al., “Calcium Pterin as an Antitumor Agent,” International Journal of Pharmaceutics 271:293-300 (2004).
Winkler, C., et al., “Calcium-Pterin Suppresses Mitogen-Induced Tryptophan Degradation and Neopterin Production in Peripheral Blood Mononuclear Cells,” Immunobiology 211:779-784 (2006).
Stea, B., et al., “Folate and Pterin Metabolism by Cancer Cells in Culture,” Cancer Research 38:2378-2384 (1978).
Moheno Phillip
Pfleiderer Wolfgang
Berch Mark L
Jaisle Cecilia M
SanRX Pharmaceuticals, Inc.
Wilson Sonsini Goodrich & Rosati
LandOfFree
Dipterinyl calcium pentahydrate (DCP) and therapeutic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dipterinyl calcium pentahydrate (DCP) and therapeutic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dipterinyl calcium pentahydrate (DCP) and therapeutic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4225043